Herriot Tabuteau, M.D., the CEO of Axsome Therapeutics, brings a unique blend of medical expertise and business acumen to his role. With an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School, he has a strong...

Herriot Tabuteau, M.D., the CEO of Axsome Therapeutics, brings a unique blend of medical expertise and business acumen to his role. With an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School, he has a strong foundation in both medicine and management. Dr. Tabuteau founded Axsome Therapeutics in 2012 and has been steering its growth ever since. Under his leadership, the company focuses on developing novel therapies for serious central nervous system disorders. His commitment to the mission is evident in the way he has structured the company's performance-based compensation system, which aligns executives' pay with the company’s success. Notably, in 2022, he received over $1.3 million in total compensation, a testament to his significant contributions to the company's achievements. Outside of his work at Axsome, he also founded Antecip Capital, emphasizing his deep involvement in the biotech industry. With a birthday in June 1975, he continues to be at the forefront of innovation in the medical field while pushing Axsome towards impactful drug development.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

A

Herriot Tabuteau, M.D.

Founder and CEO of Axsome Therapeutics

Education

M.D. from Yale University School of Medicine, B.A. in molecular biology and biochemistry from Wesleyan University

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1969 - 56 years ago

CEO of Axsome Therapeutics for

13 years 5 months (Jan 2012 - Present)

Previous Experience

Senior Analyst and Partner at Healthco/S.A.C. Capital

Rivals

Competitors/colleagues of Herriot Tabuteau, M.D.

J

Bruce C. Cozadd

Founder and CEO of Jazz Pharmaceuticals

2011 Compensation

Stock

$3.08M

Salary

$563.17K

Bonus

$552.00K

Other

$1.71K

Total Holdings

$61.64M

Holdings

See how much did Herriot Tabuteau, M.D. make over time.

As the CEO of Axsome Therapeutics, Herriot Tabuteau has been acutely aware of the fluctuations in his stock holdings. His most significant wealth was tied up in Axsome shares during key developmental phases of the company. Over the years, his...

As the CEO of Axsome Therapeutics, Herriot Tabuteau has been acutely aware of the fluctuations in his stock holdings. His most significant wealth was tied up in Axsome shares during key developmental phases of the company. Over the years, his compensation has seen considerable variation, with 2022 marking a peak with total earnings of over $1.3 million, which included a large bonus. In earlier years, he did not have vested stock compensation, focusing more on cash incentives instead. This strategy indicates a strategic choice to align with performance metrics rather than stock grants. It highlights a clear understanding of market dynamics and corporate growth, making him a significant figure in the biotech landscape.

Mar 11, 2025

A

shares

AXSM @ $118.96

Insider Trading

See recent insider trades of Herriot Tabuteau, M.D..

No insider trades found for this CEO.

Compensation History

See how much did Herriot Tabuteau, M.D. make over time.

Dr. Herriot Tabuteau's compensation reflects his vital role as CEO of Axsome Therapeutics. In 2023, he earned a total of approximately $1.31 million, consisting of a base salary of $750,000 and a bonus of $562,500 tied to corporate and personal performance metrics. Notably, the bonus structure is based on various performance goals, demonstrating a commitment to aligning executive incentives with company growth. Interestingly, there were no stock grants that vested in 2023, a pattern seen in previous years where cash compensation remained the focus. For instance, the previous year he had a large compensation package that included around $828,000 from vested stock, but that was a unique case for 2022. This highlights a strategic approach to compensation and performance metrics at Axsome, positioning the company strongly within the competitive biotech sector.

Year

2023

Total Compensation

$1.40M

Salary

$750.00K

Board Justification

The compensation program is designed to attract, motivate, and retain talented executives, aligning their interests with those of shareholders through performance-based incentives.

Bonus

$562.50K

Board Justification

Cash incentive payments made under annual incentive plans based on the achievement of corporate goals and individual performance, paid in March following completion of the performance year.

Other

$82.96K

Board Justification

Represents NEO's portion of FICA tax payments paid by the Company on behalf of the NEO due to delayed settlement of corresponding RSUs.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the focus is on cash and other compensation.

Performance Metrics

Annual cash bonuses based on operational, commercial, clinical, strategic, and other performance goals.